- Patient with Severe Sickle Cell Disease Producing 45% Anti-sickling Hemoglobin at Six Months and Has Been Free of Transfusions for More Than Three Months
- Patients with Beta-thalassemia Major Remain Transfusion-Independent at 16 and 14 Months, Respectively
- First Patient with Severe Sickle Cell Disease Infused in HGB-206 Study
Investor Conference Call Scheduled for June 15, 2015 at
8:00 a.m. ET
May 2015, Subjects 1201 and 1202 with beta-thalassemia major remained transfusion-independent for 16 and 14 months, respectively, with persistent stable expression of HbAT87Q. Neither has experienced a LentiGlobin-related adverse event.
- As of
Sickle Cell Disease:
- The proportion of anti-sickling hemoglobin being produced by the first-ever patient with severe SCD treated with gene therapy (Subject 1204) is rising steadily and accounted for 45% of all hemoglobin production (40% HbAT87Q + 5% HbF) at the patient’s six-month visit post-drug product infusion; this is above the 30% threshold expected to potentially achieve a disease-modifying clinical effect.
May 2015, Subject 1204 had been free of transfusions for more than three months without complications or hospitalizations for SCD-related events post-transplant, and with improvement in hemolysis markers.
“These data are promising for patients living with beta-thalassemia major and severe sickle cell disease, two devastating, genetically-based hematologic diseases that have a profound impact on both quality of life and life expectancy,” said Professor Cavazzana. “The steady rise and high-level of HbAT87Q production in our patient with severe sickle cell disease is cause for optimism as we expect levels of anti-sickling hemoglobin of 30 percent or more could significantly improve and potentially eliminate the serious and life-threatening complications associated with sickle cell disease.”
bluebird bio also announced that the first patient with severe SCD has
been infused in the HGB-206 U.S.-based clinical study at the
“Today’s data further demonstrate the potentially transformative effects of gene therapy for the treatment of beta-hemoglobinopathies and support our global regulatory strategy for LentiGlobin in beta-thalassemia major, with the goal of potentially accelerated approvals in the EU and U.S.,” said David Davidson, M.D., chief medical officer, bluebird bio. “We are excited that the promising early results for LentiGlobin in beta-thalassemia major are now extending to the first treated patient with severe sickle cell disease. With the treatment of the first patient with severe sickle cell disease in the HGB-206 study, we look forward to gaining increasing clarity on the potential clinical benefit of LentiGlobin for patients with severe sickle cell disease.”
HGB-205 Study Data
HGB-205 is an ongoing, open-label, single-center Phase 1/2 study designed to evaluate the safety and efficacy of LentiGlobin BB305 product candidate for the treatment of patients with beta-thalassemia major and severe SCD. As of
Patients with beta-thalassemia major demonstrated continued
transfusion independence: The data presented today are an update
on those initially presented at EHA in
June 2014and demonstrate a long-term stable and durable response. As reported at ASH in December 2014, Subjects 1201 and 1202 achieved rapid transfusion independence with near-normal hemoglobin levels. As of May 2015, Subjects 1201 and 1202 remained transfusion independent for 16 and 14 months, respectively.
Early efficacy data is promising in the first subject with severe
SCD treated with gene therapy: The production of anti-sickling
hemoglobin is consistent with a level expected to potentially achieve
a disease-modifying clinical effect in Subject 1204. At the six-month
visit post-drug product infusion, the proportion of anti-sickling
hemoglobin (HbAT87Q + HbF) accounted for 45% of all
hemoglobin production (40% HbAT87Q + 5% HbF). The patient’s
vector copy number in peripheral blood leukocytes was 2.2.
Subject 1204 had his last red blood cell (
RBC) transfusion at day 88. Since his infusion with LentiGlobin, this patient has had no hospitalizations, and has demonstrated improvements in markers of hemolysis, including normalization of reticulocyte count (from 283.3 x 109/L to 131.7 x 109/L) and lactate dehydrogenase (LDH) (from 626 U/L to 254 U/L).
- Subject 1204 had his last red blood cell (
|Beta Thalassemia Major||
|Country of Origin||Syria||France||France|
|Transfusion requirements (mls/kg/year)||139||188||170|
|CD34+ VCN in drug substance||1.5||2.1||1.2/1.0*|
|CD34+ cell count (x106/kg) in drug substance||8.9||13.6||5.6|
|Days to neutrophil engraftment||Day +13||Day +15||Day +37|
|HbAT87Q/total Hb (g/dL) at last visit||7.3/10.5||9.7/12.8||4.3/10.6|
|Last study follow up (months)**||15||15||6|
*If more than one drug substance was manufactured for a subject, the VCN of each drug substance lot is quantified and the cell count is combined.
** Last scheduled study visit for which results were available as of
In the HGB-205 study, treatment with our LentiGlobin BB305 product candidate has been well-tolerated to-date, with no LentiGlobin-related adverse events observed. All of the adverse events observed are consistent with myeloablative conditioning. All three subjects successfully engrafted and insertional site analyses (ISAs) demonstrate highly polyclonal reconstitution without clonal dominance.
Investor Conference Call and Webcast Information
bluebird bio will host a conference call and webcast on Monday, June 15 at
Beta-thalassemia is an inherited blood disease that can cause severe anemia. Patients with beta-thalassemia cannot make enough of the beta-globin part of hemoglobin, the protein used by red blood cells to carry oxygen throughout the body. Approximately 60,000 children are born with a serious form of the disease every year, making it one of the most common genetic diseases in the world. In its most severe form, beta-thalassemia is fatal if not treated.
Treating beta-thalassemia includes frequent and lifelong blood transfusions, which deliver red blood cells to the body to correct the anemia. However, blood transfusions also cause excess iron to build up in the body, which can damage organs and cause additional issues, such as abdominal pain, weakness, fatigue, joint pain, endocrine dysfunction, liver cirrhosis and heart failure. Patients who receive ongoing blood transfusions must also receive treatment to remove the excess iron. The only currently available curative treatment option for beta-thalassemia is allogeneic hematopoietic stem cell transplant. However, these transplants are typically offered to pediatric patients with matched related donors (occurring in less than 25 percent of all cases), due to the significant risk of transplant-related morbidity and mortality.
About Sickle Cell Disease
Sickle cell disease (SCD) is a hereditary blood disorder resulting from a mutation in the beta-globin gene that causes polymerization of hemoglobin proteins and abnormal red blood cell function. The symptoms of SCD include anemia, vaso-occlusive crises (a painful complication caused by obstruction of the blood vessels), infections, stroke, and progressive end-organ damage leading to overall poor quality of life and early death in a large subset of patients. The global incidence of SCD is estimated to be 300,000 births annually, and the global prevalence of the disease is estimated to be about 25 million.
Patients with severe SCD typically receive chronic blood transfusion regimens or hydroxyurea. Chronic transfusions for SCD introduce the risk of iron overload, which over time contributes to mortality through iron-associated heart and liver toxicity, and patients must adhere to daily iron chelation regimens. While hydroxyurea has been shown to significantly reduce the burden of vaso-occlusive crisis and related complications, it does not eliminate them. The only potentially curative therapy is allogeneic hematopoietic stem cell transplant (HSCT). Because of the significant morbidity and mortality risks associated with transplants, they are usually offered only to patients who have sibling matched donors and only 10 percent of SCD patients of African descent are able to find such donors.
About the HGB-205 Study
HGB-205 is an ongoing, open-label Phase 1/2 study designed to evaluate the safety and efficacy of bluebird bio’s LentiGlobin BB305 product candidate in the treatment of subjects with beta-thalassemia major and severe sickle cell disease (SCD). The study is designed to enroll up to seven subjects who will be followed to evaluate safety and transfusion requirements post-transplant. Among patients with SCD only, efficacy will also be measured based on the number of vaso-occlusive crises or acute chest syndrome events. For more information on the HGB-205 study, please visit clinicaltrials.gov using identifier NCT02151526.
About the HGB-206 Study
HGB-206 is an ongoing, open-label Phase 1 study designed to evaluate the safety and efficacy of LentiGlobin BB305 product candidate in the treatment of subjects with severe sickle cell disease (SCD). The study is designed to enroll up to eight subjects to evaluate safety and efficacy as measured by changes in red cell function tests and hemolysis markers, as well as clinical events secondary to SCD, including vaso-occlusive crises or acute chest syndrome events. For information on the HGB-206 study, please visit clinicaltrials.gov using the identifier NCT02140554.
About bluebird bio, Inc.
With its lentiviral-based gene therapy and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and T cell-based immunotherapy. bluebird bio’s clinical programs include Lenti-D™, currently in a Phase 2/3 study, called the Starbeam Study, for the treatment of childhood cerebral adrenoleukodystrophy, and LentiGlobin®, currently in three clinical studies: a global Phase 1/2 study, called the Northstar Study, for the treatment of beta-thalassemia major; a single-center Phase 1/2 study in France (HGB-205) for the treatment of beta-thalassemia major or severe sickle cell disease; and a separate U.S. Phase 1 study for the treatment of sickle cell disease (HGB-206). bluebird bio also has ongoing preclinical CAR T immuno-oncology programs, as well as discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies.
bluebird bio has operations in Cambridge, Massachusetts, Seattle,
Imagine is a research and innovative healthcare institute of a new type, bringing together researchers, doctors and patients, with a common goal: to cure genetic diseases. This new Institute is housed in a 19,000 m2 building located on the campus of the
About the AP-HP
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential efficacy and safety of the Company’s LentiGlobin product candidate, in subjects with beta thalassemia major and severe sickle cell disease, including statements concerning the reduced or eliminated need for transfusion support for the study subjects and the potential reduction in symptoms of severe sickle cell disease, statements concerning the Company’s future plans with respect to LentiGlobin and its other product candidates and statements concerning the HGB-206 clinical trial in severe sickle cell disease. It should be noted that the data for LentiGlobin announced from the HGB-205 study at the
Source: bluebird bio, Inc.
bluebird bio, Inc.
Manisha Pai, 617-245-2107
Pure Communications, Inc.
Dan Budwick, 973-271-6085